Home › All Companies › CATX › Annual Report

Perspective Therapeutics, Inc. (CATX) — Annual Report

AI-Powered SEC Filing Analysis

← All CATX filings
Latest Annual Report Filed: 2026-03-16

Key Insights

  • The company has incurred significant research and development expenses, suggesting it is investing heavily in new product development.
  • The company has raised capital through various public offerings and warrant issuances, indicating it may be funding its operations and growth initiatives.
  • The company has discontinued its Cesium-131 business, potentially shifting its strategic focus to other areas.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Perspective Therapeutics, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.